Streetbeat News

Equity Actions

APCX

CDLX

GDS

MESO

MKC

OPGN

STOK

U.S. stocks saw gains with the Dow Jones up by 100 points. McCormick & Co Inc reported better-than-expected Q1 results, with sales growth of 3% and an adjusted EPS of 63 cents. Stoke Therapeutics, Mesoblast Ltd, and OpGen Inc saw significant share price increases due to positive developments. Conversely, Cardlytics Inc, GDS Holdings Ltd, and AppTech Payments Corp experienced notable declines in their share prices.

Portfolio Pulse from Avi Kapoor

March 26, 2024 | 4:08 pm

AAPL

On CNBC, Jason Snipe announced that he is adding to his position in Apple, indicating a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 4:03 pm

APCX

AppTech Payments Corp. (APCX) shares have declined following the announcement of a $2 million underwritten public offering. This move indicates the company is seeking to raise capital, potentially diluting existing shareholders.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 4:01 pm

FIS

Fidelity National Info (NYSE:FIS) has been the subject of 11 financial analyst ratings over the last three months, showing a diverse range of opinions. The average 12-month price target for FIS has been raised to $73.27, indicating a 9.52% increase from the previous target. Analysts from firms including Evercore ISI Group, Baird, and Goldman Sachs have adjusted their ratings and price targets, reflecting a generally positive outlook on the company's performance. Despite challenges in revenue growth and below-average ROE and ROA, FIS's net margin outperforms industry averages, and its debt management is considered conservative.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

JKHY

Jack Henry & Associates (NASDAQ:JKHY) has been evaluated by 4 analysts over the last three months, all maintaining an indifferent stance. The average 12-month price target for JKHY has been raised to $176.5, marking an 11.01% increase from the previous target of $159. Analysts from Evercore ISI Group, RBC Capital, Baird, and Citigroup have adjusted their price targets, reflecting a positive outlook on the company's financial performance, including a 7.99% revenue growth and strong financial health indicators such as net margin and ROE.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

ABBV

The analysis of AbbVie (NYSE:ABBV) against its biotechnology industry competitors reveals a mixed financial health. AbbVie's PE ratio is significantly higher than the industry average, suggesting overvaluation. However, its PS ratio indicates potential undervaluation based on sales. The company's ROE is below the industry average, pointing to inefficiency in profit generation from equity. Despite this, AbbVie has a high EBITDA and gross profit, indicating strong profitability. Its revenue growth is lower than the industry average, raising concerns about future growth prospects. The debt-to-equity ratio places AbbVie in a moderate position among its peers.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

EW

Edwards Lifesciences (NYSE:EW) received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for EW has increased to $91.56, up from $83.12, indicating a positive outlook from analysts. Key financial indicators such as revenue growth, net margin, ROE, ROA, and debt management reflect the company's strong market position and financial health. Edwards Lifesciences, a leader in medical devices for structural heart disease, shows solid performance and potential for future growth.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

AAPL

The article provides a detailed comparison of Apple (AAPL) against its competitors in the Technology Hardware, Storage & Peripherals industry, focusing on financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Apple shows potential undervaluation based on its P/E ratio, high asset valuation as per its P/B ratio, strong revenue generation capability indicated by its P/S ratio, and efficient operations reflected in its high ROE, EBITDA, and gross profit. However, its lower revenue growth compared to the industry average suggests a need for strategies to enhance sales.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

ODFL

Old Dominion Freight Line (ODFL) has seen a 13.46% increase in its short percent of float since the last report, with 2.30 million shares sold short, representing 2.36% of available shares. This indicates a bearish market sentiment towards ODFL, although it has less short interest compared to its peer group average of 3.58%. The rise in short interest doesn't necessarily predict a price drop but suggests increased bearishness among traders.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

A

An extensive analysis of Agilent Technologies (NYSE:A) against its competitors in the Life Sciences Tools & Services industry reveals potential undervaluation based on PE, PB, and PS ratios. Despite this, Agilent's lower ROE suggests less efficiency in profit generation. Its EBITDA aligns with the industry average, indicating comparable operational efficiency. However, its revenue growth lags behind the industry, posing potential future challenges. Agilent's lower debt-to-equity ratio compared to top peers suggests a stronger financial position.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm